Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh Twitter profile

Pinned Tweet

Ash Alizadeh, MD/PhD 🇺🇸

3 months

Excited to share our new study of risk of T-cell #lymphomas after #CAR therapy. 1/15 🧵

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy | NEJM

The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern. We reviewed our ...

www.nejm.org

12

68

210

Last Seen Profiles

@ApendiA35025

@mustafaaakemal

@x_kallen

@semby2x

@ahmed22759446

@luorentong

@DrJamelah

@hshjahwbbd21738

@aldosseri77

@huang57823

@irvinghernadez

@morgan47750809

@ebisaki_iori

@bokeplokalmalam

@david620707

@Yuzhuyizhai

@bemi198

@MangoTam3

@cavincasino

@Parker_Direct

@Vibratiwall

@rnd

@Tommysluts

@SabanDijan

@toki_trade

@Mangodegorila

@ACLUVA

@GgsvhS69152

@Szzzzzj1

@CukiPepePapua9

@cjptog

@fatsatakip

@baeyu_bworld

@OptimusPriHN

@saiirisqx

@wsmsmsw135534

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Excited to share our new study introducing #EPICSeq out today @NatureBiotech !

Inferring gene expression from cell-free DNA fragmentation profiles

Nature Biotechnology - EPIC-seq predicts expression of individual genes from cell-free DNA.

www.nature.com

14

125

523

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Very excited to share our new study on determinants of resistance to anti-CD19 CAR T-cells (CART19) in large B-cell lymphomas (LBCLs)! Out today in @Cancer_Cell /1

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

Sworder et al. develop and apply a tool to simultaneously profile tumor and effector-mediated determinants of resistance to anti-CD19 CAR T cells using cell-free DNA. The authors profile two indepe...

www.cell.com

9

89

374

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Very excited to share our two new studies & EcoTyper out today @Cell @CancerCell . 1/13

The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma

Steen et al. implement EcoTyper, a machine-learning approach for dissecting cellular heterogeneity in the most common blood cancer, diffuse large B cell lymphoma (DLBCL). Forty-four cell states...

www.cell.com

8

76

268

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Delighted to share our new study introducing PhasED-Seq out today @NatureBiotech .

7

67

230

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

9 months

Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today @Nature . #lymsm 1/15 PDF link at bottom of this thread

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

Nature - The potential use of circulating tumour DNA in classic Hodgkin lymphoma detection, classification and monitoring is defined.

www.nature.com

22

82

231

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

Very excited to share our new study on precursor lesions in follicular lymphoma #FL , out now in @CD_AACR #lymsm 1/12 🧵

10

52

210

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

I'm brokenhearted by the loss of my friend & colleague, Steve Coutre, a giant in #hematology . Steve trained & mentored me & inspired many to love & pursue #hematology . He touched the lives of many patients & peers as a clinician, scientist, & leader. My thoughts are w/ his family

30

12

207

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Wow. Humbled & honored to have our study of #cfDNA #liquidbiopsy for #CARTcell #celltherapy of #lymsm called a "compelling" & "tour-de-force" w "vivid prognostic insights" by @NatRevClinOncol @MarcelaMaus @Mark_Leick @Cancer_Cell

5

19

168

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

Do you remember the vigorous April 2023 discussion after #ODAC vote & #FDA approval of #polatuzumab for #DLBCL & #HGBCL ? Well, with @ac_palmer & Dave Kurtz, we now tackle this more through meta-analysis @NEJM … 1/n

Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin | NEJM

Analysis of previous trials of polatuzumab vedotin for diffuse large B-cell lymphoma showed that the drug was more effective for tumors of one subtype (activated B cell) than those of another subty...

www.nejm.org

5

46

131

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Holy wow. Humbled to see that #CIBERSORT ranks among the fastest growing biology software tools!

5

11

130

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Excited to share this labor of love from @JurikMutter @StefanAlig @mohamshah @max_diehn and team showcasing the power of #PhasEDSeq #ctDNA #MRD for brain lymphomas:

Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain...

PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably heterogeneous, yet identification of patients at high risk for treatment failure is challenging. Furthermore, CNSL...

ascopubs.org

4

30

108

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Very excited to share our new study out today in @JCO_ASCO , deciphering the biological basis for the Diagnosis to Treatment Interval (DTI) in lymphoma and relationship to #ctDNA tumor burden. #lymsm

Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in...

PURPOSE Patients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy are largely under-represented in clinical trials. The diagnosis-to-treatment interval (DTI) has recently been...

ascopubs.org

1

29

87

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

9 months

Very excited to share our new study measuring clinical specificity of #immunoglobulin based high-throughput sequencing #IgHTS for #MRD measurement in mature B-cell #lymphomas . #lymsm

Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in...

TO THE EDITOR:

ashpublications.org

3

8

63

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

I’m broken-hearted and at a loss for words for our tragic loss of Sam Gambhir. He was not only a giant in the field, but also my friend, teacher, and role model. My deepest condolences to Aruna and Sam’s family. @StanfordMed @StanfordCancer @StanfordRad @StanfordDeptMed

6

1

60

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Stay tuned for how liquid biopsies CAN provide the morphology and immunophenotyping essential to lymphoma diagnosis….

Lymphoma Hub

@lymphomahub

3 years

CONGRESS | #PPLC21 | Jeremy S. Abramson @MGHMedicine discusses the future of ctDNA in NHL and how this tumor-derived genetic material has the potential (emphasis on potential) to aid in diagnosis, prognosis, MRD detection, and identification of targetable mutations #lymsm

0

5

16

1

11

54

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

So excited to have my trainees presenting their work at #ASH2019 in 7 orals and 2 posters. So proud of them for their unwavering energy, commitment, and passion for #lymphoma research!

4

8

57

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

@DrAEvens Acknowledged indeed, esp given thousands of brave DLBCL pts & investigators who endured >20 yrs in more than a dozen trials, $billions spent, & famous Rx casualties along this path including Imbruvica, Revlimid, Velcade, Gazyva, Avastin, etc. Illustrated below (Kurtz/Alizadeh)

4

17

50

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Congrats to my dear friend & long time collaborator @max_diehn for this most deserved honor!

Stanford Radiation Oncology

@StanfordRadOnc

3 years

Dr. Max Diehn ( @max_diehn ) elected to the National Academy of Medicine for his work on liquid biopsies and precision medicine. This is one of the highest honors in the field of medicine. Diehn is the 4th current @StanfordRadOnc faculty in @theNAMedicine .

27

19

204

1

3

46

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

Congrats to the terrific MARIA #deeplearning team led by @Stanford MSTP Binbin Chen. Thanks to generous support from @StanfordMed @StanfordDeptMed @stanfordimmuno @CellStanford @StanfordCancer @NIH @NCIgenomics @ASH_hematology @LLSResearch @DamonRunyon @PDSoros @TheVFoundation

Nature Biotechnology

@NatureBiotech

5 years

Predicting HLA class II antigen presentation through integrated #deeplearning - @AshAlizadeh

1

31

50

3

13

45

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

These sobering results make me wonder if #ACIP #CDC should recommend revaccinating lymphoma pts with full primary series + booster not only after CART but also after CD20 mAbs? @EricTopol @CDCDirector @KottonNelson

Tanaya Shree

@tanaya_shree

3 years

B cell depletion from anti-CD20 tx hinders new antibody responses – many great studies on this; here’s our @StanfordMed data in lymphoma patients using a surrogate virus neutralization assay: #lymsm #COVID19Vaccine @BCD_AACR @AshAlizadeh @schroersmartin @beygi_sara 1/n

5

14

50

3

14

43

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Creole Dinner with Alizadehlab lymphomaniacs!

2

0

44

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

We are grateful for generous support from @NIH @NCIgenomics @SU2C @ParkerICI @Ludwig_Cancer @DamonRunyon @LLSResearch @StanfordCancer @AACR @LLSResearch @SusanWojcicki , to our patients & their families for enabling this @StanfordMed @MSKCC collaboration .

Barzin Nabet

@Barzin_

4 years

1/11 Very excited that our paper is out today in @CellCellPress . A fantastic collaboration from @StanfordCancer with @mohamshah @max_diehn @AshAlizadeh and Matt Hellmann @sloan_kettering taking a noninvasive approach to forecast ultimate outcomes to ICI.

9

52

143

1

41

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

Excited to share our #17ICML @icmlugano #lymsm @StanfordCancer @StanfordMed #Lymphoma & #ctDNA #liquidbiopsy #MRD presentations & Collaborations!

1

3

40

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Honored by this selection and thanks for kindly recognizing our work on follicular #NHL & led by @schroersmartin @SRoulland @max_diehn & @AmericanCancer team! #lymsm

John P. Leonard, MD

@JohnPLeonardMD

3 years

Now for #LeonardList key #ASH21 #Lymphoma abstract number 8 – 709 – Schroers-Martin – Tumor-confirmed Follicular Lymphoma mutations detectable in blood years prior to clinical diagnosis

1

4

31

0

5

38

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

9 months

⁦ @schroersmartin ⁩ rocking the podium at #ASH23 with his multimodal studies of #FL #ctDNA including transformation

1

5

37

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

What an auspicious moment toward equity in science for a magnificent discovery that has shifted our paradigms. Congrats Dr Charpentier and Dr Doudna for this most well deserved recognition.

The Nobel Prize

@NobelPrize

4 years

BREAKING NEWS: The 2020 #NobelPrize in Chemistry has been awarded to Emmanuelle Charpentier and Jennifer A. Doudna “for the development of a method for genome editing.”

727

24K

48K

1

5

31

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Thanks for the kind words & admit we didn’t expect this either, even if we are very proud of the work & the promise of these results leveraging #PhasEDSeq for #CNS #lymphoma A labor of love by by @FSchererMD @StefanAlig Jurik Mutter @max_diehn #ASH21 #lymsm

Graham Collins

@graham74GC

3 years

Wasn't expecting primary CNS lymphoma in plenary #ASH21 ! Mutter et al. PCNSL mutn in ctDNA in 78% cases (plasma) & 100% (CSF) Could be developed into non-invasive diagnostic Changes assoc with prognosis (PFS & OS) - could guide treatment decisions during Rx. Impressive. #lymsm

2

18

95

0

3

34

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

7 months

An amazing collaboration with @lisa_wagar led by @Jkastens_phd @schroersmartin on what we thought was impossible. Grateful for support of @LLSusa @LLSResearch @Lymphoma @NIH @NCI @LudwigCancer @StanfordMed @StanfordCancer So grateful to our patients & families for participating.

Lisa Wagar

@lisa_wagar

7 months

Yes, you can make immune organoids from primary follicular lymphomas AND test immunotherapies on them! Congrats to co-first authors @Jkastens_phd @schroersmartin and couldn't have done this work without the incredible FL expertise of @AshAlizadeh

9

24

92

0

5

35

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

A bittersweet moment, with hopes for a brighter day for the Women of Iran... #MahsaAmini

TIME

@TIME

2 years

The Women of Iran are TIME's 2022 Heroes of the Year #TIMEPOY

2K

27K

95K

0

30

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

10 months

A comprehensive & careful analysis that dispelled many of my own misperceptions about synergy vs additivity of combos

Adam C Palmer

@ac_palmer

10 months

New paper: Most approved drug combinations for advanced cancer (1995-2020) have predictable clinical efficacy, because they have additive effect on Progression-Free Survival times. In @NatureCancer at by @HaeunHwangbo @SC_Patterson @PlanaDeborah 1/6

9

149

500

0

7

32

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

Is it just me, or does it seem surreal to have an NIH Director (to rightly) advise ignoring CDC advice on testing? Doesn’t it seem a very slippery slope when public health guidelines are driven by politics instead of data and common sense?

1

5

31

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

Thanks to all involved to make this remarkable collaboration possible, including investigators @StanfordCancer @StanfordMed @MayoClinic @MDAndersonNews @VanderbiltU @fredhutch @UW @WUSTLmed @harvardmed @MGHMedicine @HHMINEWS

Jake Chabon

@JakeChabon

4 years

1/13 – I’m excited to share that our study, “Integrating genomic features for non-invasive early #lungcancer detection” was published today in @Nature . This has been my main project for ~4 years, and I am thrilled to finally share the fruits of my labor!

7

54

218

3

2

30

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

. @graham74GC thanks for the kind appraisal of work w @FSchererMD ! we are working hard on steps to bring this to our patients!

Graham Collins

@graham74GC

3 years

Scherer - ctDNA and PCNSL - 67 pts 1ry or isolated 2ry CNSL - CSF ctDNA PhaseSEQ nearly all pts, plasma in many - preRx plasma ctDNA & tumour burden corr with outcome - Pl ctDNA during Rx also prognostic - CSF ctDNA v spec for diag Really important work #ASH21 #lymsm

1

16

67

1

5

30

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM):

0

1

27

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Excited to share our #ASH21 @StanfordCancer @StanfordMed #Lymphoma & #ctDNA Collaborations!

2

4

27

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Wow. Honored to have two lightning bolts& elegance ascribed to #PhasEDSeq !! Excited to further demonstrate *impact* from key studies by @ForesightDx that will be presented soon!

0

1

26

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

0709: #ctDNA identifies #FollicularLymphoma Progenitors w @schroersmartin @SRoulland @max_diehn

2

8

26

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

Awesome work from Stefanie Meyer, Laura Pasqualucci, and team! targeting. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma

1

10

25

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

It's always a pleasure to sit on thesis committees of brilliant students who can invent, hack, and discover, doing so in applying engineering principles to biology and medicine. Congrats Dr Still & @stanleyqilab !

Joy Wu, MD, PhD

@JoyYWu

4 years

Smiling faces on the thesis committee after a successful @StanfordBiosci @CellStanford PhD defense. One of the greatest joys of being a professor. Congratulations DR. Chris Still @stanleyqilab ! @AshAlizadeh

0

1

22

0

1

25

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

I learned the horrifying Sabatini news from a colleague, deeply concerned for their child's academic future, as a PhD student among the 39. We should stand united in providing ample support & refuge for such surviving trainees, to avoid their further trauma, & to learn from them.

0

25

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

@StanfordCancer & Collaborations #16ICML #002 : Architecture of #lymphoma #liquidbiopsy #006 : #AxiCel #CART19 #ctDNA (plenary) #023 : CHIP & cfDNA in DLBCL #025 : PhasED-Seq #MRD in DLBCL #046 : PhasED-Seq #PCNSL w @FSchererMD #139 : CIRI2 for CLL w #GCLLSG @Othman_Al_Sawaf

1

13

24

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

Excited to share #CIRI , extending in-game win likelihood models to #cancer outcomes, using precision genomics & dynamic measures including #ctDNA #MRD for diverse cancers! Looking forward to the possibilities for our patients.

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction

A framework for the integration of cancer-patient biomarker data over time improves prognostic accuracy and could inform personalized therapy selection.

www.cell.com

2

3

21

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

9 months

Excited to share our #ASH23 @ASH_hematology #lymsm @StanfordCancer @StanfordMed #Lymphoma & #ctDNA #liquidbiopsy #MRD presentations & other collaborations this weekend! #lymsm

2

5

23

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

In absence of prospective RCTs targeting CNS risk w agents like MTX, could we do better than murky retrospective data alone? Eg, what if baseline CSF #ctDNA predicts CNS relapse risk (in the absence of cytological evidence) & prospectively show that rx like MTX can eradicate it?

chadi nabhan MD, MBA, FACP

@chadinabhan

3 years

This is very nice and well-balanced summary by @graham74GC on role of CNS prophylaxis in DLBCL. I’ll say that we won’t ever have pros def data, so decisions (including changing practice) will be based on current best available “retro” evidence. @mattwilson2287 @AaronGoodman33

0

7

4

2

23

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Congrats @HowardYChang !

National Academy of Sciences

@theNASciences

2 years

In recognition of his contributions to genome science, Howard Y. Chang of @Stanford is being inducted into the National Academy of Sciences. Watch the #NAS159 livestream:

18

29

539

1

0

23

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

Distinct molecular determinants of treatment-failure in elderly Hodgkin lymphoma identified by cell-free DNA profiling: A LYSA Study #PhasEDSeq @LysaLymphoma Cedric Rossi @StefanAlig @schroersmartin @mohamshah @max_diehn @TakeshiSugio @nonoscherlebeck

Distinct molecular determinants of treatment‐failure in elderly Hodgkin lymphoma identified by...

Click on the article title to read more.

onlinelibrary.wiley.com

3

2

22

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Congrats @JakeChabon & @ForesightDx team on this exciting effort to improve the lives of our patients using #liquidbiopsy . Excited to see what we can accomplish with sharper, more efficient, and more precise tools for #MRD .

Jake Chabon

@JakeChabon

3 years

Our company @ForesightDx is officially out of stealth mode! I am honored to be part of an excellent scientific founding team out of @StanfordMed with @AshAlizadeh @max_diehn and David Kurtz. Stay tuned for more info to come about the company and our technology! #ctdna #cancer

3

38

0

4

22

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

Whoops somehow the #17icml dinner photo didn’t stick on prior tweet.

1

21

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

9 months

@JohnPLeonardMD Why replace imaging when the results complement? We learned how to fuse CT with PET, and we are now learning how to combine ctDNA with imaging. FWIW, there are now a lot more ctDNA data today than there were for metabolic imaging in lymphoma.

0

3

21

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

To conclude, the effect of DLBCL cell of origin on polatuzumab efficacy was established by prior studies, & confirmed by 2 RCTs. Should this now inform precision medicine in DLBCL? 12/EOT. #lymsm @lymphoma @LLSusa @lymphomahub @DrAEvens @dgermain21 @MaurerStats @RoschewskiMD

4

2

22

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Fascinating that response to and benefit from Acala in 1L seems agnostic to COO and so rapidly discernible with #ctDNA . Excited to consider opportunities to personalize Rx based on such results!

Foresight Diagnostics Inc.

@ForesightDx

3 years

Our PhasED-Seq #ctDNA liquid biopsy strongly correlates with standard of care CT imaging in #DLBCL patients and remarkably identifies treatment response to acalabrutinib in only 7 days. Read the #ASH21 abstract (524) here: @AshAlizadeh

0

4

16

0

4

20

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

@MaartenvSmeden So that I could get emails with attachments that I would need to print out then sign then scan then re-attach to email then send back.

0

20

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Thanks @everettmoding for this terrific synthesis! Hoping this review of #liquidbiopsy #ctdna #MRD & analysis of prior studies helps us pave a clearer path ahead toward better outcomes for our patients!

Everett Moding, MD, PhD

@everettmoding

3 years

Happy to share our data-driven review of circulating tumor DNA ( #ctDNA ) minimal residual disease ( #MRD ) in solid cancers now out in @CD_AACR . @Barzin_ @AshAlizadeh @max_diehn

3

42

118

2

4

18

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

7 months

What a privilege to have a physician scientist at the helm!

William Shi

@williamyshi

7 months

So wonderful to welcome @NCIDirector back to Stanford and join @stanfordcbio students for lunch! We really appreciate the wisdom you imparted, both at the talk and @StanfordCancer round table

3

4

62

0

1

20

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Excited for the opportunities to apply this next generation of MRD technologies for more sensitive detection of lymphomas and other cancers.

Sabarish Ayyappan MD

@SabarishMD

3 years

#16ICML David Kurtz and @AshAlizadeh group, PhasED Seq more sensitive and specific for MRD testing in DLBCL. Potential for MRD adapted and personalized approach to lymphoma therapy.

0

2

7

0

2

19

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Very interesting use of CIBERSORTx for cfRNA deconvolution!

sevahn vorperian

@skayaneh

3 years

check out our preprint -- cell free RNA liquid biopsy can readily be decomposed at cell type resolution!

1

6

11

0

3

19

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

Together, our findings suggest a model of FL where BCL2 lesions are 1st, followed by accumulation of other mutations including CREBBP leading to clinical #lymphoma . Identifying the founding events of this cancer helps us identify important targets for #FL treatment. 10/12

4

2

19

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

Proud to share this labor of love by ⁦ @mohamshah ⁩ and team at ⁦ @StanfordMed ⁩ ⁦ @StanfordCancer ⁩ Functional significance of U2AF1 S34F mutations in lung adenocarcinomas | Nature Communications

Functional significance of U2AF1 S34F mutations in lung adenocarcinomas

Nature Communications - The authors report a co-occurrence of the U2AF1 S34F splicing factor mutation and ROS1 translocations in lung adenocarcinomas and profile effects of S34F on...

www.nature.com

0

7

19

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

@aadel_chaudhuri What “ivory tower” are we really talking about? Academic physician scientists must sacrifice so much for the love of each part of the trifecta, that it seems slanderous to conflate the requisite probity of this calling with a privileged seclusion from “the real world”.

1

18

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Excited to see all the #ASH21 Plenary Presentations! Good luck @FSchererMD !

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

0006: #PhasEDSeq for #PCNSL w @FSchererMD @StefanAlig @max_diehn (Plenary!)

1

2

13

1

3

19

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

We thank all #lymphoma patients & families for participating in these studies & honored by support from @StanfordCancer @AACR @StanfordMed @LLSusa @lymphoma @NIH @NCI @Ludwig_Cancer @CanceropolePACA @Ludwig_Cancer @DamonRunyon @ASH_hematology enabling this work. #lymsm 12/12 EOT

4

0

16

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

How might these new #ctDNA data inform next pivotal #PCNSL study after MATRix/IELSG43 #LBA #ASH22 ? @DrAEvens @dgermain21 @graham74GC @CwynKate @DrMiguelPerales @drkomanduri @timfenske @majorajay @MediHumdani @GeraldIllerhaus @lymphomahub @RoschewskiMD @MaurerStats @DrJasonWestin

Stefan Alig

@StefanAlig

2 years

#ctDNA has great potential across cancers, yet its assessment in CNS lymphomas (CNSL) is more challenging because of low allelic levels, due to 1) lower tumor volumes and 2) decreased ctDNA shedding related to the blood-brain barrier. Does ctDNA still have value in CNSL?

1

7

36

1

5

18

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

MARIA and friends in action: Potential T-cell and B-cell Epitopes of 2019-nCoV | bioRxiv

Potential T-cell and B-cell Epitopes of 2019-nCoV

As of Feb 16th 2020, 2019-nCoV has infected more than 51,857 people across 26 countries and claimed 1666 lives. 2019-nCoV is a novel form of coronavirus that causes COVID-19 and has high similarity...

www.biorxiv.org

0

2

17

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

#CIBERSORTx is our latest, extending RNA #deconvolution beyond enumeration, leveraging #scRNAseq for digital cell sorting from bulk mixtures! Excited about possibilities for #tumor #immunology .

Determining cell type abundance and expression from bulk tissues with digital cytometry

Nature Biotechnology - CIBERSORTx, a suite of computational tools, enables inference of cell type abundance and cell-type-specific gene expression profiles from bulk RNA profiles.

www.nature.com

2

0

18

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Wow. Honored by the kind comments of @KenLauLab . Instead of continuing to think of cancers as isolated "islands", we look forward to connecting many more tumor biomes as "continents" linked to relevant clinical context using #EcoTyper

0

4

18

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

@jeff_sharman The genuine pursuit of the academic mission to advance knowledge, doing so as a core part of the job description, not as a bystander luxury or perk of the job.

1

18

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

When you mix complex immunology with Fox News politics, sadly you get Fox News politics. Glad to have @SetteLab @profshanecrotty to the rescue, and to interpret their own data.

Prof. Shane Crotty

@profshanecrotty

4 years

1/ There are various tweets misinterpreting COVID-19 “pre-existing immunity” and making dangerous claims about herd immunity. Since many of those claims refer to our scientific papers, we will reiterate the facts. @SetteLab @ljiresearch @ScienceMagazine @CellCellPress

130

2K

4K

0

1

18

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

MRD-NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS @RoschewskiMD @ForesightDx @Lymphoma_Doc @Rcl14L @OpatStephen @NCIResearchCtr @MorphoSys

MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS

Click on the article title to read more.

onlinelibrary.wiley.com

1

4

17

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

A beautiful synthesis of the state of FL risk & risk directed strategies by @DrCarlaCasulo . Would love opportunities to collaborate on ctDNA in FL as informing m7, POD24, tFL risk, and beyond.

Fernando Martín Moro

@Fer_martinmoro

3 years

Upfront identification, by @DrCarlaCasulo @WomenInLymphoma : - Pt: FLIPI, PRIMA-PI - Tumor: histology, microenvironment & genetics - Baseline SUVmax >14-18 - ctDNA (combine with MTV) - Early progression 🚨 Towards finding predictive markers for a personalized approach! #16ICML

1

3

16

1

4

16

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Apologies to all of you encountering the the Elsevier paywall. This URL should provide unfettered access for the next 50 days or so.

0

1

17

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

Our dream team of lymphomaniacs at our team lab dinner at #icml : @StefanAlig left early to practice his talk! @schroersmartin Cedric Rossi, @bsworder Jan Bögeholz

1

0

15

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Spatial-CUT&Tag: Spatially resolved chromatin modification profiling at the cellular level

0

4

16

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

Circular ecDNA promotes accessible chromatin and high oncogene expression

Nature - Imaging and sequencing approaches are combined to show that extrachromosomal DNA (ecDNA) in cancer is circular and has unique chromatin structure that amplifies oncogene output.

www.nature.com

0

3

16

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Wow, that's quite the endorsement from a seasoned veteran in therapeutics and diagnostics for lymphoma!

Foresight Diagnostics Inc.

@ForesightDx

3 years

We’re pleased to announce the addition of Sandra Horning, MD to the Foresight Diagnostics Scientific Advisory Board. A seasoned clinician and biopharmaceutical executive, Dr Horning brings a keen interest in clinical MRD utilization. #lymphoma

0

1

8

0

2

16

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

9 months

Party time for Kurtz & Alizadeh lab #ASH23 !

0

1

15

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

A cancer survivor had the longest documented COVID-19 infection. Here’s what scientists learned | Science | AAAS

A cancer survivor had the longest documented COVID-19 infection. Here’s what scientists learned

Yearlong infection spawned a striking mutation beyond SARS-CoV-2’s spike protein

www.science.org

0

1

13

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

Eliminate ABIMs MOC requirement - Sign the Petition! via @Change

3

1

14

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

For example, this patient of mine discontinued therapy against medical advice for Stage IV DLBCL after only 1 rx cycle. This patient is nevertheless now alive without disease >6 years later, and was MRD-negative by PhasED-Seq just 25 days after start of therapy...

1

0

13

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

We set out to tackle this challenge by developing #EcoTyper (), a novel algorithmic framework for cell state & ecosystem discovery & validation from bulk, single-cell, and spatially resolved expression data. 4/

1

9

15

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

Yippee Dr Kate Rubins @Astro_Kate7 ! Hope your 2nd @Space_Station mission is as awesome as the 1st! I miss your @StanfordMed days but can only marvel at all you have accomplished since then! Hope @NASA ballot boxes up there are less messy than down here to #VOTE ! #WomenInScience

NASA

@NASA

4 years

Welcome home! With the Soyuz hatch opened at 7:07am ET, the @Space_Station crew has doubled. Astronaut Kate Rubins and cosmonauts Sergey Ryzhikov and Sergey Kud-Sverchkov are now residents of our orbiting laboratory:

95

1K

7K

0

14

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

Interesting result. Beyond BL and T-ALL, I wonder if such MYC-driven NK deficits extend to MYC+ DLBCL and DHL, and if so, whether this could inform therapeutic strategies w CAR NK.

Steven Artandi, MD, PhD

@SCIDirector

4 years

SCI member Dean Felsher and colleagues demonstrate a systemic reduction in natural killer (NK) cell numbers in mice bearing MYC-driven T-lymphomas. Targeting NK cells in future therapies may lead to effective treatment of these cancers. @LabDfelsher

1

4

14

1

13

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

Thanks @LLSreseach , @EricTopol , @NCIgenomics , @Jonathancmwan , for the kind words. We look forward to bringing you CIRI for many other tumor types soon, and excited to now work on translating these ideas for our pts.

Leukemia & Lymphoma Society Research

@LLSResearch

5 years

#CIRI – a new method out in @CellCellPress to predict outcomes of #cancer patients at any point in their diseases by @AshAlizadeh and Maximilian Diehn with Drs. Kurtz, Esfahani, and Scherer @StanfordMed @Stanford . #cancerresearch

0

6

14

0

13

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Congrats for this most well deserved recognition!

Joe Schroers-Martin, MD

@schroersmartin

3 years

Thrilled and humbled to be the recipient of a 2021 ASCO YIA! Thanks to outstanding mentorship from @AshAlizadeh , @max_diehn , @KiranKhush1 . Looking forward to digging deeper in early detection and lymphomagenesis! @StanfordCancer

5

2

29

0

1

13

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

Harold Varmus and friends share a compelling perspective: The Lack of Testing Is Holding Science Back - The Atlantic

0

1

13

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

7 months

Lineage-specific intolerance to oncogenic drivers restricts histological transformation | Science

Lineage-specific intolerance to oncogenic drivers restricts histological transformation

Neuroendocrine-specific tolerance to Myc is an oncogenic driver underlying histological transformation of lung cancer.

www.science.org

0

2

13

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

0006: #PhasEDSeq for #PCNSL w @FSchererMD @StefanAlig @max_diehn (Plenary!)

1

2

13

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

In #DLBCL , integrated profiling of >2.5k bulk tumors and >170k single cells by scRNA-Seq allowed us to discover & validate 44 cell states for 13 cell types, which together define 9 Lymphoma Ecotypes. 6/

1

4

11

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

The hospital stopped my cancer treatment to make room for pandemic overflow

0

3

12

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

1 year

@schroersmartin Packed room at the TME session and tons of questions for @schroersmartin about his awesome talk!

1

2

12

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

Yowza. Jay does it again.

0

12

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

This makes it urgent for us to do dedicated trials of RNA vaccines in immuno compromised hosts to assess their efficacy and safety.

Eric Topol

@EricTopol

4 years

How to accelerate #SARSCoV2 evolution, a fairly slowly evolving virus, for the potential of functional mutations 1. Infection of immunocompromised hosts 2. Give convalescent plasma (without evidence) to hundreds of thousands of people w/ covid 3. Use ? effective vaccine regimens

23

222

604

0

2

11

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

This study would not have been possible without the many contributions from the co-authors @StanfordCancer including @JakeChabon @mohamshah @co_keh @StefanAlig @everettmoding @emham @michael_c_jin @DrBinSquared @macaulay_cw @schroersmartin @schultzdre & others

1

0

11

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

5 years

Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death | Nature

Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death

Nature - The authors find that loss of squalene monooxygenase expression alters the lipid metabolism of cancer cells, which confers protection from ferroptotic cell death and thus promotes tumour...

www.nature.com

0

2

12

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

Alterations in multiple classes of genes were associated with resistance, including B-cell identity (PAX5 and IRF8), immune checkpoints (CD274/PD-L1) and those impacting the microenvironment (TMEM30A). /7

1

11

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

4 years

@deniswirtz visualizing heterogeneity within an individual tumor seems most valuable when that insight is generalized to other pts and many more tumors over space (and time). TMAs are a powerful tool for this, as is #cfdna #ctdna . Can 3D TME methods be applied to thousands of tumors today?

1

12

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

@DrAEvens @AaronGoodman33 @graham74GC @Lymphoma_Doc 1st: begin by avoiding contaminating the literature w underpowered studies that claim RCHOP is sufficient for MYC+ and DHL/THL, when large studies have reproducibly shown otherwise.

2

0

10

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

Sad to see a giant in science and medicine step down as our NIH leader.

1

11

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

9 months

Abstract #4369 Rossi et al, Distinct Circulating Genomic Features of Classical #Hodgkin Lymphoma of #Older Adults #Elderly #cHL #ctDNA #EBV #PhasED -Seq @LysaLymphoma #CedricRossi @nonoscherlebeck

1

4

11

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

3 years

@JohnPLeonardMD Remarkably potent and an important advance for our patients. Yet these seemingly high CRS and ORR rates across Ph2 trials beg for some direct comparisons in future trials (when?) to give us a real sense of our choices in rrNHL #lymsm

0

11

Ash Alizadeh, MD/PhD 🇺🇸

@AshAlizadeh

2 years

A fantastic collaboration from @StanfordMed and @StanfordCancer led by Brian Sworder, David Kurtz, @StefanAlig , and Matthew Frank with David Miklos & @Max_Diehn to help improve outcomes following CAR T-cell therapy in lymphomas & beyond /2

1

0

10